Related Experiment Video
Updated: Aug 14, 2026

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
Budgetary considerations in planning pharmacy continuing education programs
Abstract:
This article presents three years of financial data on pharmacy continuing education programs offered by a college of pharmacy. Forty-one programs were offered resulting in the generation of 35,702 instructional units of activity and 3028.8 CEUs. Total costs were $295,797.00 of which $125,822.00 was for direct costs. Income totaled $127,754.00. Costs and income per registrant, instructional unit, and program are presented, as are comparative data by program type for the three-year period. The total cost of one hour of programming for one participant was $8.29. Some thoughts on who should pay for the costs of CE for professionals are presented. Figures are discussed in light of situational factors influencing program delivery. Staff productivity was determined to be 11.7 programs per FTE or 13.7 programs per year. This last figure translated to serving 2,654 participants per year. Total income accounted for only 43.2 percent of total expenses. Increase in registration fees was suggested as one way to offset all expenses.
More Related Videos
07:31A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
Published on: February 13, 2020
13:44Project-Based Learning Guidelines for Health Sciences Students: An Analysis with Data Mining and Qualitative Techniques
Published on: December 9, 2022
Related Concept Videos
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Dosage Regimens: Designs and Approaches
Dosage Regimens: Partial Pharmacokinetic Parameters
Dosage Regimen: Individualization
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions